Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 1.00 |
| ▸ | CNR1 | P21554 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387466 | 1.00 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29388381 | 0.91 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL669446 | 0.89 | CNR2 (0.81) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29989065 | 0.88 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL6332169 | 0.88 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29989734 | 0.86 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL6327412 | 0.86 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29988425 | 0.85 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL497044 | 0.84 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29988469 | 0.84 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013106460-A2 | COMPOSITIONS AND METHODS FOR TREATING MALIGNANT ASTROCYTOMAS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | CNR2 1/4885CNR1 2/4885MEN1 1930/4885 |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CNR2 1823/4885CNR1 2351/4885MEN1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.